Experts exploring what other conditions semaglutide, the active ingredient in Wegovy and Ozempic, might help apart from diabetes and weight loss say the results of a Phase 3 clinical trial suggest it may reverse a common liver disease.

There could be a new use for semaglutide, the main ingredient of weight loss and diabetes drugs Wegovy and Ozempic. Dr. Jon LaPook explains a study sponsored by the drugmaker found it could treat a common liver disease by reducing inflammation and scarring.

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, according to the New England Journal of Medicine.